-
Signature
-
/s/ Heidy King-Jones, as Attorney-in-Fact
-
Issuer symbol
-
SYRE
-
Transactions as of
-
29 May 2025
-
Net transactions value
-
$0
-
Form type
-
4
-
Filing time
-
02 Jun 2025, 16:36:29 UTC
Quoteable Key Fact
"Mark C. McKenna filed Form 4 for Spyre Therapeutics, Inc. (SYRE) on 02 Jun 2025."
Quick Takeaways
- This page summarizes Mark C. McKenna's Form 4 filing for Spyre Therapeutics, Inc. (SYRE).
- 1 reported transaction and 1 derivative row are listed below.
- Filing timestamp: 02 Jun 2025, 16:36.
What Changed
- Previous filing in this sequence was filed on 08 Jan 2025.
- Current net transaction value: $0.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| McKenna Mark C. |
Director |
221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM |
/s/ Heidy King-Jones, as Attorney-in-Fact |
02 Jun 2025 |
0001749623 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
SYRE |
Stock Option (Right to Buy) |
Award |
$0 |
+25,000 |
|
$0.000000 |
25,000 |
29 May 2025 |
Common Stock |
25,000 |
$15.55 |
Direct |
F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses: